Hi bdalarge and Endicot,
This is just very highlighted stuff:
-Cash as at Nov 30 was confirmed to be $2.2mm
-Many interested pharms from small to very large
-explaination why Provalis,
--"impressed with their marketing strategy",
--UK does not allow direct to consumer advertising (as done in NA) so the 'cash size' of the partner is not as important
--no HMO like organization, but a practice group, worked hard to prepare the way, March launch
--very important was the pricing for pennsaid
-- not disclosed upfront fee was received and significant margin on sales
RE $50mm financing
-credentials on Acqua Wellington, a leader in equity line of credit
-draw down on cash when needed and "when we want it"
-at a price beneficial so minimize dilution
-use of funds, aggressive expansion - drug delivery
-will have next product into clinicals this year (calendar? or fiscal?)
-eve of commercialization with the funding
-""positioned to implement the business plan""
No, Q&A!!
I was expecting the other special s/h were privy to the call in number. But guess not.
Rennie Ho asked two questions and my rough notes pasted below.
QA
1. RH: 42 sales rep for pennsaid is that enough?
-fx of reps, calls to handle
-satisfied, enough coverage
-number of pharm they talked to , small to very large
-no direct consumer advertising
-necessary to have that large cash partner
-convinced to go with provalis -- results of the clinical studies not the marketing
-sampling is limiteed and controlled
-smaller may also be successfull marketing
-impressed by Prov marketing strategy
2. RH: procodures in EU and progress
-regulatory environment, mca acting as agent for europe
-shortly
-british gov to summary dossier, then other nations has 90 days to reject
-negotiating for some time to EU, etc proceeding, expectation to have partners in place by time approval is received
So, no submission to the EU countries yet. Time to reset the calendar. |
